Answers are grounded in this paper and cite their sources.
Generating drug-like molecules while balancing chemical validity, synthetic accessibility, novelty, and distributional fidelity is a multi-objective optimization problem. We present HybridMolGen as a categorical two-dimensional molecular graph diffusion backbone refined with proximal policy optimization (PPO), a balanced within-batch marginal-rank reward, and adaptive objective weights. The evaluated implementation neither generates Cartesian coordinates nor includes an independently evaluated SE(3)-equivariant coordinate generator or cross-attention property-conditioning module. In an eight-seed paired confirmation with 256 samples per condition, refinement increased synthetic-accessibility utility by 0.00610 (95% bootstrap CI 0.00106 to 0.01061), novelty by 0.00928 (0.00342 to 0.01465), and composite utility by 0.00632 (0.00153 to 0.01068). Hypervolume changed by − 0.00021 and satisfied the predefined non-inferiority gate. A frozen checkpoint was subsequently evaluated with the official MOSES implementation on 25,000 requested samples. Relative to the matched backbone, FCD/Test improved from 0.57250 to 0.55633 and scaffold similarity from 0.90221 to 0.91031, whereas validity changed from 0.87756 to 0.87488 and novelty from 0.94076 to 0.93936. The results support a controlled policy-refinement trade-off rather than universal superiority. Three-dimensional equivariant generation and explicit cross-attention conditioning remain future extensions requiring independent implementation and evaluation.
No takes yet. Share an insight, caveat, or question.
Amiri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: